Actualités

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]

The drugmaker should significantly mitigate its most important risk as it develops new products.

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...

Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...

Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...

It's been a volatile year for the company, but don't let that scare you away.

It is getting acquired by a larger firm in the sector.

With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.

Additional blockbuster drugs may be on the horizon.

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]

Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?

Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...

Shares of Vera Therapeutics rose about 8% Tuesday after the Food and Drug Administration approved its treatment for a kidney disease, IgA nephropathy, that affects about 160,000 people in the U.S. and often leads to kidney failure. The drug, called Trutakna, works by blocking two proteins that push the immune system to make antibodies that build up in the kidneys and cause damage. It is the first drug approved in the U.S. that targets both proteins at once, though several other drugs already treat the disease.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.